Donepezil and memantine combination therapy may offer modest added benefit for some people with moderate-to-severe Alzheimer's disease, but it is not appropriate for every dementia. Those most likely to qualify have established moderate or severe Alzheimer's, already tolerate donepezil, and can use memantine safely; risks include digestive problems, dizziness, confusion, constipation, fainting, and heart-rate problems.
Combination therapy means taking both medicines, either separately or in a fixed-dose capsule called Namzaric. The March 2026 U.S. label for Namzaric limits it to moderate-to-severe dementia of the Alzheimer's type in people stabilized on donepezil 10 mg daily.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- How much benefit does the combination provide?
- Who may qualify?
- What risks need attention?
- What about other forms of dementia?
- How should families evaluate a trial of treatment?
How much benefit does the combination provide?
In a 24-week randomized trial, 404 people with moderate-to-severe Alzheimer's continued donepezil and received either memantine or a placebo. Adding memantine produced statistically better cognition, daily-function, overall-condition, and behavioral scores, according to the 2004 JAMA study. Discontinuation because of adverse events occurred in 7.4% of the combination group and 12.4% of the placebo-plus-donepezil group.
This supports short-term tolerability among selected trial participants, but it does not predict how every patient will respond. Longer-term evidence is less encouraging. A 52-week New England Journal of Medicine trial found no significant advantage over donepezil alone on its primary cognition or daily-living outcomes. Taken together, the trials suggest that added benefit is possible but generally modest and not assured.
Who may qualify?
The strongest case is a person with an established diagnosis of moderate or severe Alzheimer's disease who already takes and tolerates donepezil. For the U.S. fixed-dose product, stabilization on 10 mg of donepezil daily is a specific labeling requirement.
NICE guidance in the United Kingdom recommends considering memantine alongside an acetylcholinesterase inhibitor, such as donepezil, for moderate Alzheimer's disease and offering the combination for severe Alzheimer's disease. "Consider" leaves room for clinical judgment rather than making combination treatment automatic. A prescribing review should cover:.
- The dementia diagnosis and current severity
- The current donepezil dose and any side effects
- Kidney function, particularly severe impairment
- Heart-rate, fainting, digestive-bleeding, seizure, lung, and bladder-outflow history
- Which changes in daily function, behavior, or cognition would count as worthwhile
What risks need attention?
The FDA donepezil label lists nausea, diarrhea, vomiting, reduced appetite, insomnia, fatigue, and muscle cramps. It also highlights bradycardia, or an abnormally slow heart rate, heart block, fainting, gastrointestinal-bleeding risk, seizures, asthma or COPD, and bladder-outflow problems. The donepezil label and memantine label should inform the safety review.
Memantine commonly causes dizziness, headache, confusion, and constipation. Its target dose must be reduced in severe kidney impairment, and the drug can accumulate when urine pH rises. New fainting, worsening confusion, persistent digestive effects, or suspected gastrointestinal bleeding deserves prompt contact with the prescribing team. A pharmacist should also review medicines and conditions that may raise urine pH.
What about other forms of dementia?
A dementia diagnosis alone does not establish eligibility. The cause matters because evidence and recommendations differ among Alzheimer's, Lewy-body, and frontotemporal dementias.
NICE permits limited, diagnosis-specific treatment for Lewy-body dementia, including donepezil and memantine when acetylcholinesterase inhibitors are unsuitable. It advises against either medicine for frontotemporal dementia. Someone with an uncertain diagnosis should have the dementia type clarified before combination therapy is considered.
How should families evaluate a trial of treatment?
Before treatment begins, ask what benefit is realistically expected and how it will be measured. Useful observations might cover everyday tasks, behavior, alertness, confusion, appetite, bowel habits, dizziness, and fainting.
Keep a short dated record rather than relying on general impressions. Bring that record, an updated medication list, and any new symptoms to follow-up so the prescriber can judge whether the possible benefit outweighs the adverse effects.
